The top-line decline and persistent net losses signal ongoing competitive and structural headwinds. The RMB1.1B redemption liability from the failed STAR listing is a critical liquidity risk — monitor for further repayment milestones or restructuring agreements. Positive operating cash flow provides a buffer, but the asset-light pivot has yet to stabilize revenue. Watch for Q1 2026 results to see if the divestiture strategy improves margins.
Price Chart
Executive Summary
111, Inc. filed its annual 20-F for FY2025, reporting a 12.8% decline in total net revenue to RMB12.6 billion ($1.8B) driven by a 12.7% drop in B2B product revenue and a 14.5% drop in B2C product revenue, attributed to heightened competition and a strategic shift to an asset-light model via subsidiary divestitures. The company narrowed its net loss slightly to RMB22.5 million ($3.2M) from RMB20.8 million in 2024, while generating positive operating cash flow of RMB119.1 million. A material overhang remains: RMB1.1 billion in redeemable non-controlling interests and accrued liabilities related to 1 Pharmacy Technology's failed STAR Market listing, with RMB282.2 million already repaid and 57.2% of investors agreeing to restructured repayment terms.
Key Facts
- Total net revenue declined 12.8% YoY to RMB12.6 billion ($1.8B) in FY2025 from RMB14.4 billion in FY2024.
- B2B product revenue fell 12.7% to RMB12.2 billion ($1.7B); B2C product revenue fell 14.5% to RMB223.2 million ($31.9M).
- Net loss was RMB22.5 million ($3.2M) in FY2025, compared to a net loss of RMB20.8 million in FY2024.
- Positive operating cash flow of RMB119.1 million ($17.0M) in FY2025, down from RMB263.0 million in FY2024.
- RMB1.1 billion in redeemable non-controlling interests and accrued liabilities related to 1 Pharmacy Technology's failed STAR Market listing; RMB282.2 million already repaid.
- Cash and cash equivalents stood at RMB511.0 million ($73.1M) as of Dec 31, 2025.
- Company divested three subsidiaries in Q3 2025 as part of an asset-light strategy; these contributed ~20% of 2024 consolidated net revenue.
- Service revenues declined 19.8% to RMB85.4 million ($12.2M) due to lower B2B digital marketing revenue.
Financial Impact
Revenue declined 12.8% YoY; net loss slightly widened to RMB22.5M from RMB20.8M; operating cash flow positive but halved to RMB119.1M.
Risk Factors
- RMB1.1 billion redemption liability from 1 Pharmacy Technology investors could strain liquidity if further repayment demands accelerate.
- Continued revenue contraction from intensified competition and the asset-light transition may delay a return to profitability.
- Regulatory and geopolitical risks from operating in China, including potential PCAOB access issues and CSRC filing requirements for future offerings.
- Dual-class share structure concentrates voting power with founders, limiting minority shareholder influence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 13 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001104659-26-052002 |
| Document: yi-20251231xex12d2.htm | 0001104659-26-052002 |
| Document: yi-20251231xex12d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex8d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex13d2.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d3.htm | 0001104659-26-052002 |
| Document: yi-20251231xex13d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d1.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d4.htm | 0001104659-26-052002 |
| Document: yi-20251231xex15d2.htm | 0001104659-26-052002 |
| Document: 0001104659-26-052002-index-headers.html | 0001104659-26-052002 |
| Document: 0001104659-26-052002-index.html | 0001104659-26-052002 |
| Document: 0001104659-26-052002.txt | 0001104659-26-052002 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $2.86 | awaiting T+60 | — | $3.00 (+4.90%) |
Sep 28, 2026 29d ago | 6-K | $3.52 | awaiting T+60 | — | $3.00 (−14.77%) |
Sep 17, 2026 5w ago | SC 13D | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (+15.25%) |
Sep 17, 2026 5w ago | 6-K | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Sep 17, 2026 5w ago | Press Release | $3.54 | awaiting T+60 | — | $3.00 (−15.25%) |
Jun 16, 2026 19w ago | Insider Cluster | $4.45 $3.45 | ▼ −22.47% | ▼ −23.47% | $3.00 (−32.58%) |
Jun 12, 2026 19w ago | Insider Cluster | $4.89 $3.20 | ▲ +34.56% | ▲ +37.82% | $3.00 (+38.65%) |
Jun 4, 2026 20w ago | 6-K | $4.72 $3.46 | ▲ +26.69% | ▲ +28.58% | $3.00 (+36.44%) |
May 29, 2026 21w ago | Insider Cluster | $5.28 $3.53 | ▼ −33.14% | ▼ −34.33% | $3.00 (−43.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers